GlassScriptPhysician profile
Jeniece Alison Cooper
NPI 1861015596
$4,370.39
in general payments reported to CMS, 2019-2025
22 companies · $2,287 in 2025
The $2,287 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $364 · 2024: $1,720 · 2025: $2,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,370.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $728.88 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $560.45 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $558.50 | 2023-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $498.12 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $346.12 | 2023-2025 | |
| Amgen INC. | $281.26 | 2023-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $272.01 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $265.77 | 2023-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Phathom Pharmaceuticals, INC. | $265.27 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $91.48 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.87 | 2023-2025 | Synjardy, Jardiance, Tradjenta |
| Dexcom, INC. | $77.51 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $69.89 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $56.09 | 2024-2025 | |
| Indivior INC. | $54.42 | 2024-2025 | Sublocade |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $43.11 | 2024 | Keveyis |
| Merck Sharp & Dohme LLC | $23.58 | 2025 | Gardasil 9, Rotateq, Capvaxive |
| Axsome Therapeutics, INC. | $20.19 | 2025 | Auvelity |
| Abbott Laboratories | $18.62 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.34 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $16.47 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $16.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeniece Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.